Completed PHASE1 INTERVENTIONAL 2-arm NCT00934817

Dose Proportionality Study Comparing Amaryl-M 1/500 mg and Amaryl-M 2/500 mg

An Open, Randomized, Two-Treatment, Crossover Study to Assess the Dose Proportionality of Glimepiride Between Amaryl M 1mg/500mg and 2mg/500mg (Glimepiride-Metformin Fixed Dose Combination Tablet) in Healthy Subjects

Sponsor: Handok Inc.

Conditions Healthy

Interventions Amaryl-M 1/500 mg Amaryl-M 2/500 mg

Updated 6 times since 2017 Last updated: Jul 7, 2009 Started: Mar 31, 2007 Primary completion: May 31, 2007 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00934817, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Handok Inc., it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jul 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jul 2019 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Handok Inc.

Data source: Handok Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.